Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The firm said with a 4Q revenue beat preannounced the ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

At this time, I would like to welcome everyone to the 10x Genomics Fourth Quarter and Full Year 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high resolution. Genomics and sequencing ...